Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for INS-IGF2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | INS-IGF2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native fold. |
View INS-IGF2 Products |
| Gene Delivery | INS-IGF2 Promise-ORF / Lentivirus Full-length readthrough ORF for stable cell line generation and signaling assays. |
View INS-IGF2 Products |
| Benchmark Ab | Anti-INS-IGF2 Recombinant Antibody Sequence-verified positive control targeting the readthrough junction epitope. |
View INS-IGF2 Products |
| Validator | INS-IGF2 siRNA Set Target-specific knockdown pool for validation of functional readouts. |
View INS-IGF2 Products |
| Related Target A | IGF1R Primary signaling receptor mediated by INS-IGF2 in oncogenic transformation. |
View IGF1R Products |
| Related Target B | INSR Insulin receptor isoform A/B crossover binding partner for metabolic and mitogenic signaling. |
View INSR Products |
| Related Target C | IGF2 Wild-type homolog; critical counter-screening target to ensure drug selectivity. |
View IGF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity with WT Insulin and IGF2 | High-purity recombinant INS-IGF2 junction-specific proteins and WT controls for differential ELISA/SPR. |
| Conformational Integrity of Fusion Protein | HEK293 expression system ensures correct disulfide bond formation and native glycosylation. |
| Lack of Controls | Sequence-verified benchmark antibodies targeting the unique readthrough peptide sequence. |
| False Positives in Signaling Assays | Validated siRNA knockdowns and lentiviruses available to establish clean baseline responses. |
Live INS-IGF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the INS-IGF2 readthrough transcript is emerging as a highly specialized frontier in oncology. Unlike wild-type Insulin or IGF2, INS-IGF2 represents a tumor-associated neo-antigenic fusion that is overexpressed in specific solid tumors, including colorectal, breast, and pancreatic cancers. The race for INS-IGF2 therapeutics is shifting focus from systemic IGF1R/INSR blockers to highly specific monoclonal antibodies and antibody-drug conjugates (ADCs) that selectively target the readthrough junction, minimizing the risk of severe metabolic side effects like hypoglycemia.
As next-generation biologics enter preclinical pipelines, developers are prioritizing the validation of target-specific binding kinetics. The key to commercial success lies in demonstrating zero cross-reactivity with physiological insulin, making rigorous in vitro screening assays the primary bottleneck in early development.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic & Biotech Consortia | Colorectal Cancer, Breast Cancer | Selectivity Screening (Need pure WT Insulin, WT IGF2, and INS-IGF2 proteins) |
| Antibody-Drug Conjugate (ADC) | Oncology-focused Biopharma | Solid Tumors (Pancreatic, Ovarian) | Internalization Assay (Need Lentivirus for stable overexpressing cell lines) |
| siRNA / RNAi Therapeutics | RNAi Specialists | Metabolic Disorders, Oncology | In vitro knockdown verification (Need validated siRNA sets and qPCR controls) |